The US Cancer Institute is currently studying ivermectin's potential as a cancer treatment, despite concerns and a lack of conclusive evidence. The National Cancer Institute, led by Anthony Letai, is investigating ivermectin's ability to kill cancer cells, despite the drug's lack of proven efficacy against COVID-19 and the skepticism of career scientists within the agency. This decision has sparked debate, with some questioning the allocation of taxpayer funds for preclinical studies based on nonscientific ideas. Ivermectin, primarily used for parasitic infections, has been promoted by fringe groups and online influencers as a miracle cure, including for cancer, despite a lack of evidence supporting its safety and effectiveness in human cancer treatment. The FDA has warned against large doses of ivermectin due to potential dangers, including seizures and death. Critics argue that the push for ivermectin research may be driven by political and financial motives, rather than scientific merit. The National Institutes of Health's openness to unconventional ideas has raised concerns about the integrity of scientific research and the potential for misinformation. The study's findings are expected in a few months, and the NCI's decision to explore ivermectin's potential as an anticancer therapy remains a topic of debate among scientists and the public.
